DRUG
Bright Minds Biosciences Inc.
Biotechnology
Market Cap$864M
5Y Perf.+232.0%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
DRUG vs CYBN
Revenue, margins, valuation, and 5-year total return — side by side.
CYBN
Cybin Inc.
Biotechnology
Market Cap$304M
5Y Perf.-83.3%
DRUG vs CYBN — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | DRUG | CYBN |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $864M | $304M |
| Revenue (TTM) | $0.00 | $0.00 |
| Net Income (TTM) | $-11M | $-123M |
| Total Debt | $126K | $0.00 |
| Cash & Equiv. | $83M | $135M |
DRUG vs CYBN — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
DRUG
CYBN
| Stock | Mar 21 | May 26 | Return |
|---|---|---|---|
| Bright Minds Biosci… (DRUG) | 100 | 332.0 | +232.0% |
| Cybin Inc. (CYBN) | 100 | 16.7 | -83.3% |
Price return only. Dividends and distributions are not included.
Quick Verdict: DRUG vs CYBN
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: CYBN leads in 3 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Bright Minds Biosciences Inc. is the stronger pick specifically for recent price momentum and sentiment and operational efficiency and capital deployment. As sector peers, any of these can serve as alternatives in the same allocation.
DRUG
Bright Minds Biosciences Inc.
The Long-Run Compounder
DRUG is the clearest fit if your priority is long-term compounding.
- 228.9% 10Y total return vs CYBN's -99.7%
- +195.1% vs CYBN's -1.9%
- -13.1% ROA vs CYBN's -58.3%
Best for: long-term compounding
CYBN
Cybin Inc.
The Income Pick
CYBN carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 1.52
- EPS growth 93.5%
- Lower volatility, beta 1.52, current ratio 7.75x
Best for: income & stability and growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | CYBN | -57.3% revenue growth vs DRUG's -305.3% |
| Quality / Margins | CYBN | 3.2% margin vs DRUG's 1.3% |
| Stability / Safety | CYBN | Beta 1.52 vs DRUG's 1.87 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | DRUG | +195.1% vs CYBN's -1.9% |
| Efficiency (ROA) | DRUG | -13.1% ROA vs CYBN's -58.3% |
DRUG vs CYBN — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLDRUGLAGGINGCYBN
CYBNCybin Inc.
0leads
DRUGBright Minds Bioscien…
3leads
6 Total Categories
CATEGORYLEADERvs CYBNMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
DRUG1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
DRUG4/6
Total Returns1Y, 3Y, 5Y total returns with dividends
DRUG6/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
DRUG leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
DRUG and CYBN operate at a comparable scale, with $0 and $0 in trailing revenue.
| Metric | DRUGBright Minds Bios… | CYBNCybin Inc. |
|---|---|---|
| RevenueTrailing 12 months | $0 | $0 |
| EBITDAEarnings before interest/tax | -$12M | -$147M |
| Net IncomeAfter-tax profit | -$11M | -$123M |
| Free Cash FlowCash after capex | -$8M | -$106M |
| Gross MarginGross profit ÷ Revenue | — | — |
| Operating MarginEBIT ÷ Revenue | — | — |
| Net MarginNet income ÷ Revenue | — | — |
| FCF MarginFCF ÷ Revenue | — | — |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | -141.2% | -8.2% |
DRUG leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — DRUG and CYBN each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | DRUGBright Minds Bios… | CYBNCybin Inc. |
|---|---|---|
| Market CapShares × price | $864M | $304M |
| Enterprise ValueMkt cap + debt − cash | $804M | $205M |
| Trailing P/EPrice ÷ TTM EPS | -94.67x | -13.66x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | — |
| Price / BookPrice ÷ Book value/share | 10.16x | 6.52x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — DRUG and CYBN each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
DRUG leads this category, winning 4 of 6 comparable metrics.
Profitability & Efficiency
DRUG delivers a -13.5% return on equity — every $100 of shareholder capital generates $-14 in annual profit, vs $-81 for CYBN. On the Piotroski fundamental quality scale (0–9), DRUG scores 4/9 vs CYBN's 3/9, reflecting mixed financial health.
| Metric | DRUGBright Minds Bios… | CYBNCybin Inc. |
|---|---|---|
| ROE (TTM)Return on equity | -13.5% | -81.0% |
| ROA (TTM)Return on assets | -13.1% | -58.3% |
| ROICReturn on invested capital | — | -115.8% |
| ROCEReturn on capital employed | -31.8% | -54.1% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 3 |
| Debt / EquityFinancial leverage | 0.00x | — |
| Net DebtTotal debt minus cash | -$83M | -$135M |
| Cash & Equiv.Liquid assets | $83M | $135M |
| Total DebtShort + long-term debt | $125,777 | $0 |
| Interest CoverageEBIT ÷ Interest expense | -541.45x | — |
DRUG leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
DRUG leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in DRUG five years ago would be worth $38,216 today (with dividends reinvested), compared to $968 for CYBN. Over the past 12 months, DRUG leads with a +195.1% total return vs CYBN's -1.9%. The 3-year compound annual growth rate (CAGR) favors DRUG at 2.1% vs CYBN's -20.5% — a key indicator of consistent wealth creation.
| Metric | DRUGBright Minds Bios… | CYBNCybin Inc. |
|---|---|---|
| YTD ReturnYear-to-date | +6.4% | -26.4% |
| 1-Year ReturnPast 12 months | +195.1% | -1.9% |
| 3-Year ReturnCumulative with dividends | +2860.5% | -49.8% |
| 5-Year ReturnCumulative with dividends | +282.2% | -90.3% |
| 10-Year ReturnCumulative with dividends | +228.9% | -99.7% |
| CAGR (3Y)Annualised 3-year return | +2.1% | -20.5% |
DRUG leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
Evenly matched — DRUG and CYBN each lead in 1 of 2 comparable metrics.
Risk & Volatility
CYBN is the less volatile stock with a 1.52 beta — it tends to amplify market swings less than DRUG's 1.87 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. DRUG currently trades 71.8% from its 52-week high vs CYBN's 62.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | DRUGBright Minds Bios… | CYBNCybin Inc. |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.87x | 1.52x |
| 52-Week HighHighest price in past year | $123.75 | $9.83 |
| 52-Week LowLowest price in past year | $23.18 | $5.50 |
| % of 52W HighCurrent price vs 52-week peak | +71.8% | +62.0% |
| RSI (14)Momentum oscillator 0–100 | 57.6 | 35.5 |
| Avg Volume (50D)Average daily shares traded | 156K | 292K |
Evenly matched — DRUG and CYBN each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates DRUG as "Buy" and CYBN as "Buy".
| Metric | DRUGBright Minds Bios… | CYBNCybin Inc. |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $136.50 | — |
| # AnalystsCovering analysts | 3 | 4 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
DRUG leads in 3 of 6 categories — strongest in Income & Cash Flow and Profitability & Efficiency. 2 categories are tied.
Best OverallBright Minds Biosciences In… (DRUG)Leads 3 of 6 categories
Loading custom metrics...
DRUG vs CYBN: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is DRUG or CYBN a better buy right now?
Analysts rate Bright Minds Biosciences Inc.
(DRUG) a "Buy" — based on 3 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — DRUG or CYBN?
Over the past 5 years, Bright Minds Biosciences Inc.
(DRUG) delivered a total return of +282. 2%, compared to -90. 3% for Cybin Inc. (CYBN). Over 10 years, the gap is even starker: DRUG returned +228. 9% versus CYBN's -99. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — DRUG or CYBN?
By beta (market sensitivity over 5 years), Cybin Inc.
(CYBN) is the lower-risk stock at 1. 52β versus Bright Minds Biosciences Inc. 's 1. 87β — meaning DRUG is approximately 23% more volatile than CYBN relative to the S&P 500.
04Which is growing faster — DRUG or CYBN?
On earnings-per-share growth, the picture is similar: Cybin Inc.
grew EPS 93. 5% year-over-year, compared to -96. 9% for Bright Minds Biosciences Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — DRUG or CYBN?
Bright Minds Biosciences Inc.
(DRUG) is the more profitable company, earning 0. 0% net margin versus 0. 0% for Cybin Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: DRUG leads at 0. 0% versus 0. 0% for CYBN. At the gross margin level — before operating expenses — DRUG leads at 0. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — DRUG or CYBN?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is DRUG or CYBN better for a retirement portfolio?
For long-horizon retirement investors, Cybin Inc.
(CYBN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Bright Minds Biosciences Inc. (DRUG) carries a higher beta of 1. 87 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CYBN: -99. 7%, DRUG: +228. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between DRUG and CYBN?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.